The global nuclear medicine market size is entering a transformative growth phase, driven by rapid adoption of theranostics, expanding oncology applications, and investment in radiopharmaceutical infrastructure. Valued at approximately USD 21.3 billion in 2025, the market is projected to grow to USD 23.5 billion in 2026 and surge to USD 61.4 billion by 2036, reflecting a robust CAGR of 10.1%. This expansion will generate an absolute dollar opportunity of nearly USD 37.9 billion over the forecast period.

Diagnostic radiopharmaceuticals currently dominate the product landscape with a 47.3% share, supported by widespread use of technetium-99m imaging agents. Oncology remains the largest application segment at 42.6%, with PET-CT imaging for tumor detection and treatment monitoring driving demand. Hospitals account for 48.9% of end-use, underscoring the central role of institutional procurement and clinical infrastructure.

Emerging markets such as China (12.4% CAGR) and India (11.7%) are reshaping global growth patterns through investments in cyclotrons, imaging systems, and radiopharmacy networks. Meanwhile, advancements in Lutetium-177 and actinium-225 therapies are expanding treatment capabilities. As the industry evolves, companies integrating imaging, therapeutics, and isotope supply are poised to capture long-term value in this high-growth nuclear medicine ecosystem.

Get Sample Report of the Report:https://www.factmr.com/connectus/sample?flag=S&rep_id=12177

Market Overview

The nuclear medicine market encompasses diagnostic and therapeutic radiopharmaceuticals alongside imaging equipment used to detect and treat diseases using radioactive isotopes. The sector has become increasingly critical in modern healthcare, particularly in oncology, cardiology, and neurology, where molecular imaging enables early detection and personalized therapy.

With the market expected to nearly triple in value between 2025 and 2036, growth is being fueled not only by rising disease burden but also by a shift toward precision medicine. Nuclear medicine technologies are becoming essential in clinical decision-making, enabling clinicians to visualize biological processes at the molecular level rather than relying solely on anatomical imaging.

Importantly, the industry is evolving from a diagnostics-led model into an integrated therapeutic ecosystem, where imaging and treatment are increasingly interconnected.

Key Growth Drivers

Several structural factors are driving sustained expansion in the nuclear medicine market:

• Theranostic adoption: The integration of diagnostic imaging with targeted radionuclide therapy is creating a new treatment paradigm, significantly increasing per-patient value.
• Breakthrough therapies: The FDA approval of Lutetium-177 PSMA therapy (Pluvicto) for metastatic prostate cancer has accelerated demand for therapeutic radiopharmaceuticals.
• Rising PET-CT utilization: Growing procedure volumes for oncology staging and treatment monitoring are driving demand for fluorine-18 (F-18 FDG) and emerging tracers.
• Infrastructure expansion: Increased investment in cyclotrons and radiopharmacy networks is improving access to short half-life isotopes in underserved regions.

These drivers collectively highlight a shift toward integrated and high-value diagnostic-therapeutic pathways.

Technology & Innovation Trends

Innovation is reshaping the nuclear medicine landscape, with theranostics emerging as the defining trend. This approach pairs diagnostic isotopes such as gallium-68 with therapeutic agents like lutetium-177 or actinium-225, enabling targeted treatment based on molecular imaging results.

Key technological advancements include:

• Development of next-generation PET tracers, including gallium-68 and copper-64 for specialized cancer and infection imaging
• Expansion of alpha-emitting therapies, particularly actinium-225, offering higher tumor-killing efficacy
• Integration of AI-assisted image analysis, improving diagnostic accuracy and enabling quantitative treatment monitoring
• Growth of hybrid imaging systems such as PET-CT and SPECT-CT, enhancing clinical precision

These innovations are not only improving patient outcomes but also reshaping revenue models, as theranostic cycles generate recurring demand across diagnostics, therapy, and follow-up imaging.

Full Report: https://www.factmr.com/report/nuclear-medicine-market

Market Challenges & Restraints

Despite strong growth prospects, the nuclear medicine market faces critical operational and structural constraints:

• Radioisotope supply chain risks: Dependence on aging reactors for molybdenum-99 and technetium-99m creates vulnerabilities in supply continuity.
• High capital requirements: PET-CT scanners and cyclotron installations involve significant upfront investment, limiting access for smaller healthcare facilities.
• Regulatory complexity: Strict radiation safety protocols and waste management requirements increase compliance costs and operational complexity.

These challenges emphasize the importance of vertical integration and infrastructure investment for sustained market participation.

Segment Analysis

By Product

Diagnostic radiopharmaceuticals lead the market, accounting for 47.3% share in 2026, driven by extensive use of technetium-based imaging agents. Their dominance reflects a large installed base and consistent demand across clinical applications.

Therapeutic radiopharmaceuticals represent the fastest-growing segment, particularly beta emitters and iodine-based therapies, as treatment paradigms shift toward targeted radionuclide therapy. Equipment, including PET-CT and SPECT systems, supports the broader ecosystem by enabling imaging and treatment planning.

By Application

Oncology dominates with a 42.6% market share, driven by applications such as tumor detection, metastasis identification, and treatment response assessment. The high prevalence of cancer and increasing reliance on molecular imaging underpin this segment’s leadership.

Cardiology and neurology remain significant, with applications including myocardial perfusion imaging and neurodegenerative disease diagnostics.

By End Use

Hospitals account for 48.9% of demand, reflecting their central role in nuclear medicine procedures and infrastructure. Diagnostic imaging centers are expanding rapidly, particularly in urban and private healthcare settings, contributing to decentralized growth.

Regional Analysis

North America remains the largest market, supported by advanced healthcare infrastructure, strong reimbursement frameworks, and high adoption of PET-CT imaging and theranostics.

Europe demonstrates stable growth, with Germany (9.6% CAGR) and the UK (9.1%) benefiting from standardized regulatory systems and institutional investments in imaging technologies.

Asia Pacific is the fastest-growing region, led by China and India:

• China (12.4% CAGR): Rapid PET-CT installation and government-backed cyclotron investment are expanding domestic production and access.
• India (11.7% CAGR): Growth is supported by BARC’s isotope production, increasing PET-CT adoption, and expanding cancer care infrastructure.

Other notable markets include the U.S. (10.9% CAGR), Brazil (10.2%), and Japan (8.4%), each driven by unique combinations of infrastructure, demographics, and clinical adoption.

Competitive Landscape

The nuclear medicine market exhibits a complex and multi-layered competitive structure, spanning imaging equipment manufacturers, radiopharmaceutical producers, and isotope suppliers.

Key competitive factors include:

• Radiopharmaceutical production and distribution capacity
• Imaging equipment installed base
• Theranostic pipeline depth
• Radiopharmacy infrastructure reach

Companies that integrate across these domains—combining diagnostics, therapeutics, and supply chain capabilities—are best positioned to capture long-term value.

Leading Companies Analysis

Prominent players shaping the nuclear medicine market include:

• GE Healthcare, a leader in imaging equipment and radiopharmaceutical production
• Jubilant Life Sciences, with strong radiopharmacy distribution networks
• Nordion, a major supplier of medical isotopes
• Bracco Imaging, specializing in diagnostic imaging agents
• IRE (Institute for Radioelements), a key European isotope supplier

Additional players such as ANSTO, NTP Radioisotopes, and Eczacıbaşı-Monrol compete through regional expertise and product specialization. Meanwhile, pharmaceutical companies like Novartis and Bayer are advancing theranostic pipelines, adding a new dimension to competition.

Investment & Strategic Developments

Recent strategic moves underscore the market’s innovation-driven trajectory:

• GE Healthcare (2026): Advanced its actinium-225 alpha therapy program into Phase 2 clinical trials, reinforcing its theranostic strategy.
• Jubilant Life Sciences (2025): Launched a next-generation digital PET-CT system, improving image quality while reducing radiation exposure.
• Nordion (2025): Expanded radiopharmacy infrastructure with three new production centers to enhance supply reliability.
• Bracco Imaging (2026): Secured approval for a gallium-68 PSMA tracer, strengthening its theranostic product portfolio.

These developments highlight increasing investment in both upstream isotope production and downstream clinical applications.

Conclusion

The global nuclear medicine market is undergoing a structural transformation, evolving from a diagnostic-focused sector into a comprehensive therapeutic ecosystem. With strong growth projections, advancing technologies, and expanding clinical applications, the market presents significant opportunities for stakeholders across the value chain.

However, success will depend on the ability to navigate supply chain constraints, regulatory complexity, and high capital requirements. Companies that leverage integrated capabilities—combining imaging, therapeutics, and isotope supply—will be best positioned to capitalize on the USD 61.4 billion opportunity by 2036, as nuclear medicine continues to redefine modern healthcare.

Top Reports:

• https://www.24-7pressrelease.com/press-release/535901/microfluidic-chip-cooling-market-set-to-reach-usd-286-billion-by-2036-as-ai-infrastructure-and-high-performance-computing-drive-next-generation-thermal-management-factmr
• https://www.24-7pressrelease.com/press-release/535950/acute-myeloid-leukemia-therapeutics-market-to-exceed-usd-101-billion-by-2036-as-p recision-oncology-and-targeted-therapies-transform-aml-treatment-landscape-factmr
• https://www.24-7pressrelease.com/press-release/535953/accelerometer-medical-sensors-market-to-reach-usd-257-billion-by-2036-as-remote-monitoring-and-wearable-healthcare-technologies-accelerate-adoption-factmr
• https://www.24-7pressrelease.com/press-release/535996/office-of-the-cfo-software-market-to-reach-usd-1987-billion-by-2036-as-ai-driven-finance-transformation-and-cloud-erp-adoption-accelerate-growth-factmr